Expert Opinion on Pharmacotherapy

Article	Citations
Oral anticoagulation therapy in the setting of liver disease	86
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook	54
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond	51
Pharmacotherapy developments in autophagy inhibitors for bladder cancer	46
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy	45
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis	41
Pivmecillinam: past, present, and future	39
Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management	39
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy	38
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten	31
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis	31
Current treatment options for Mycobacterium marinum cutaneous infections	30
Evaluation of zongertinib for the treatment of metastatic non-squamous non-small cell lung cancer with HER2 TKD activating mutation	29
How have gamma-secretase inhibitors changed the treatment landscape for desmoid tumors?	28
Evaluating linaclotide for the treatment of irritable bowel syndrome with constipation in children and adolescents	27
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives	27
Selecting optimal therapy in the evolving therapeutic landscape of metastatic pheochromocytoma and paraganglioma	26
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease	25
Wound healing pharmacotherapies: what can we expect for 2026?	25
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges	25
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan	24
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants	23
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma	23
Zanubrutinib for the treatment of chronic lymphocytic leukemia	22
Selecting optimal therapy in systemic mastocytosis: current state and future directions	22

How useful is chemotherapy for atypical and anaplastic meningiomas?	22
Pharmacologic management of ET: established therapies and emerging agents	22
Potential treatments for attention-deficit/hyperactivity disorder: a focus on Phase III trials	21
Pharmacotherapy of persistent genital arousal disorder/genito-pelvic dysesthesia: an updated review and data from a registry	21
Correction	20
How are developments in the treatment armamentarium of hyperphosphatemia addressing the current therapeutic challenges?	20
Momelotinib in myelofibrosis	20
Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?	20
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis	20
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy	20
Current advances in colorectal cancer treatment: a review of recent clinical trials	20
Expanding indications and developmental landscape of HER2-targeted therapies in breast cancer: a pharmacotherapeutic perspective	19
Microdomain-resolved potassium channel gating as a controllable process: patient-specific excitability landscapes, attractor stability, and closed-loop therapeutic optimization	18
Pharmacotherapy of treatment-resistant hypertension in patients with chronic kidney disease	18
An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies	18
Rise and fall of decongestants in treating nasal congestion related diseases	18
Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study	18
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy	18
Pharmacological treatment of anhedonic depression: the role of dopaminergic and anti-inflammatory mechanisms	17
Upadacitinib in Crohn’s disease	17
Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs	17
An update on current pharmacotherapy for vulvar cancer	17
Treating pediatric aggressive behaviors and comorbid conditions	16
Current pharmacological solutions for Behçet’s syndrome	16
Advances in the pharmacotherapeutic management of duchenne muscular dystrophy: an update	16
Recent advances in the treatment of FGFR-altered cholangiocarcinoma	16
Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy	16
Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes	16
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature	16
Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review	16
Evaluating pimavanserin tartrate as a treatment in Parkinson’s disease	16
Approved medications for opioid use disorder : current update	15
Tirzepatide for overweight and obesity management	15
Correction	15
Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment	15
Current advancements in pharmacotherapy for cancer cachexia	15
Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis	15
Benefits and disadvantages of combination therapy with imeglimin and metformin in patients with type 2 diabetes	15
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update	15
The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder	15
The role of pharmacotherapy in the treatment of endometriosis: an update	15
Recent progress in the use of pharmacotherapy for endometrial cancer	14
Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy	14
Simnotrelvir as a potential treatment for COVID-19	14
When is pharmacotherapy necessary for Tourette syndrome? The risks vs reward	14
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors	14
Pharmacogenomics and pediatric drug development: science and political power. A narrative review	14
Pharmacotherapy for cervical cancer: current standard of care and new perspectives	14
An evaluation of pharmacological options for Cushing’s disease: what are the state-of-the-art options?	13
Pharmacotherapeutic strategies for the treatment of anorexia nervosa – novel targets to break a vicious cycle	13

Recent advances in Alzheimer’s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein	13
Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma	13
Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals	13
Optimizing drug therapy for older adults: shifting away from problematic polypharmacy	13
Antiproliferative therapies in pulmonary arterial hypertension	13
Current and emerging COX inhibitors for treating postoperative pain following oral surgery	13
Evidence-based prescribing of medications for ADHD: where are we in 2023?	13
Modern pharmacotherapy guidance for treating alcohol use disorders	13
An update on recent developments in the drug treatment of tuberculous meningitis	13
Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper	13
Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments	12
Pharmacotherapy for Gastrointestinal Angiodysplasia: is it effective?	12
Response to the letter to the editor: ‘Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia’	12
Migraine in multiple sclerosis patients: potential links and treatment approach	12
Pharmacological management of pituitary adenomas – what is new on the horizon?	12
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia	12
New antibiofilm strategies for the management of nontuberculous mycobacteria diseases	12
Pharmacological management of digital ulcers in systemic sclerosis - what is new?	12
Evaluation of prescribing patterns of switching to and add-on lemborexant in patients treated with hypnotic medication: a nationwide claims database study in Japan	12
Evaluating once-weekly insulin efsitora alfa for adults with type 2 diabetes	12
Use of glucagon-like polypeptide 2 analogs for intestinal failure	12
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry	12
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date	11
Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024	11
Reassessing the role of aspirin in patients with coronary artery disease	11
Current and emerging pharmacotherapies in Lennox-Gastaut syndrome	11
Current status of intracavernosal injection therapy in erectile dysfunction	11
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?	11
Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials	11
Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis	11
Is pharmacotherapy ready to redefine the state of the art in obstructive sleep apnea care?	11
Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done?	11
Advances in the pharmacotherapeutic management of refractory peptic ulcers	11
Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms	11
Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder	11
The relationship between cognition and the pharmacotherapy of depression	11
Is supplemental vitamin D useful in the clinically isolated syndrome (CIS) typical of multiple sclerosis?	11
Melanoma and pediatric drug development: clinical progress vs. regulatory activism in minors - a narrative review	11
Evaluation of delgocitinib for the treatment of moderate to severe chronic hand eczema in adults	11
An update on the pharmacological management of acne vulgaris: the state of the art	10
Acute severe ulcerative colitis: efficacy and safety of JAK inhibitors	10
Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants	10
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19	10
Time to reconsider the way of selecting antihypertensives for hypertensive left ventricular hypertrophy	10
Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning	10
Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature	10
Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy	10
Risk management of medication errors: a novel conceptual framework	10
Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults	10
Auditory toxicity of antimalarials in systemic autoimmune diseases: a systematic review and critical appraisal	10
A review of pharmacokinetic data describing long-acting injectable cabotegravir during pregnancy	10
Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence	10
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review	10
Amyloidosis of the heart: pathophysiology, diagnosis, and treatment	10
Upadacitinib in Crohn’s disease: needs more insight	9
Pharmacotherapy in leishmaniasis: old, new treatments, their impacts and expert opinion	9
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization	9
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?	9
Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease	9
Effective risk reduction strategies and pharmacological treatment for uncomplicated recurrent urinary tract infections	9
Addressing the long-term risks of administering antenatal steroids	9
Pharmacotherapy options and drug development in bronchiectasis: spotlight on dipeptidyl-peptidase inhibitors	9
Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients	9
Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder	9
Pharmacological management of migraine: current strategies and future directions	9
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis	9
Will elinzanetant, a neurokinin receptor antagonist, have a role in the treatment of hot flashes?	9
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy	9
An update on antifungal resistance in dermatophytosis	9
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments	9
Glucocorticoid therapy and risk of venous thromboembolism: a systematic review and meta-analysis with exploration of dose, duration, and route-specific effects	9
Clinical guidance for choosing the right pharmacotherapy for migraine attacks	9
Pharmacotherapeutic approaches to treating postpartum depression: a focus on GABA A receptor positive allosteric modulators	9
Clinical, metabolic, and immune interaction between tuberculosis and diabetes mellitus: implications and opportunities for therapies	9
An update on the pharmacotherapy of gout	9
Optimisation of direct-acting oral anticoagulants (DOACs) use for atrial fibrillation (AF) and venous thromboembolism: a practical guide	9
Pharmacological treatment for children with constipation: present and future	9
New and emerging drugs for the treatment of invasive fungal infections	9
Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults	9
FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions	8

Targeted small molecules in polymyalgia rheumatica: the emerging role of JAK inhibitors beyond glucocorticoids and DMARDs	8
A systematic review on effect of sodium-glucose cotransporter-2 inhibitors on the metabolic and endocrinological profile of patients with polycystic ovarian syndrome	8
Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome	8
Promising therapies for the treatment of acromegaly	8
An evaluation of sebetralstat as the first oral on-demand therapy for Hereditary Angioedema	8
Advances in pharmacotherapy for bronchiectasis in adults	8
Metabolic-associated steatotic liver disease and hepatocellular carcinoma	8
State-of-the-art and emerging antivirals for chronic hepatitis B infection	8
Pharmacotherapy for gastric and intestinal cramping pain: ‎ current and emerging therapies	8
Pharmacotherapy for bipolar disorder in adults with high-functioning autism	8
Essential elements for guiding patient segmentation in precision pharmacotherapy for rheumatoid arthritis: lessons up to 2025	8
Current pharmacological strategies for symptomatic reduction of persistent breathlessness – a literature review	8
Treatment considerations for the pharmacotherapeutic management of constipation associated with colonic diverticular disease	8
Advances in the pharmacological management of acute myeloid leukemia in adults	8
Combining finerenone with SGLT-2 inhibitors: building up CONFIDENCE for the treatment of diabetic kidney disease	8
Impact of bladder cancer family history on the prognosis of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)	8
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis	8
The pharmacological management of alcohol-related cirrhosis: what’s new?	8
GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients	8
Oral anticoagulation with versus without antiplatelet therapy in patients with stable coronary artery disease and an indication for anticoagulation: a meta-analysis with trial sequential analysis	8
Gepotidacin in oral antibacterial pharmacotherapy: efficacy, safety, and clinical positioning	8
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?	8
Glasdegib for the treatment of acute myeloid leukemia	8
The pharmacological management of treatment-resistant depression: what does the future hold?	8
Expert guidance for treating anemia in chronic kidney disease: what is the appropriate drug treatment strategy?	7
Cardio-reno-vascular protection in type 2 diabetes mellitus: new insights into pharmacotherapeutic management	7
Post-surgical pain: evolving drug treatments and challenges	7
Novel pharmacotherapy for drug-induced immune hemolytic anemia	7
A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry’s Disease	7
Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome	7
Current factor IX replacement options for hemophilia B and the challenges ahead	7
An overview of the current drug treatment strategies for moderate to severe, chronic malignant tumor-related pain	7
Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?	7
Pharmacological management of heart failure: a patient-centred approach	7
Recent advances in EGFR-targeted therapies for non-small cell lung cancer	7
Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what’s new on the horizon?	7
Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder	7
The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis	7
Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension	7
Montelukast as a potential treatment for COVID-19	7
Venetoclax and new BCL-2 inhibitors in acute myeloid leukemia	7
Future directions for pharmaceutical management of alopecia areata in Asia	7
Polypharmacology of carbonic anhydrase inhibitors and activators	7
Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma	7
Streptozotocin in pancreatic neuroendocrine tumors: a focus on efficacy and safety	7
Paxlovid as a potential treatment for long COVID	7
How far are we from an approved drug for nonalcoholic steatohepatitis?	7
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?	7
Liposomal drug formulations for treatment of hematological malignancies	7
Clinical challenges and considerations in pharmacotherapy of osteoporosis due to menopause	7
Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia	7
Does standard pharmacotherapy still have a major role in the treatment of aggressive B-cell malignancies?	7
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond	7
Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature	7